Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov 30, 2025	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021
Revenue	83.98	54.55	76.99	38.63	29.75
Revenue Growth (YoY)	53.95%	-29.14%	99.31%	29.84%	66.95%
Gross Profit	83.98	54.55	76.99	38.63	29.75
Selling, General & Admin	52.74	45.94	42.9	38	31.2
Research & Development	316.9	221.63	189.15	184.5	116.43
Total Operating Expenses	369.65	267.58	232.05	222.49	147.64
Operating Income	-285.67	-213.03	-155.06	-183.87	-117.89
Total Non-Operating Income (Expense)	21.97	19.73	11.12	3.51	0.82
Pretax Income	-263.7	-193.3	-143.95	-180.36	-117.06
Provision for Income Taxes	0.76	0.27	-	-	0.13
Net Income	-264.46	-193.57	-143.95	-180.36	-117.19
Net Income to Common	-264.46	-193.57	-143.95	-180.36	-117.19
Shares Outstanding (Basic)	87	67	54	49	43
Shares Outstanding (Diluted)	87	67	54	49	43
Shares Change (YoY)	29.12%	23.52%	11.79%	13.32%	173.68%
EPS (Basic)	-3.05	-2.88	-2.65	-3.71	-2.73
EPS (Diluted)	-3.05	-2.88	-2.65	-3.71	-2.73
Shares Outstanding	101.81	75.87	48.72	47.17	44.66
Free Cash Flow	-263.47	-182.14	-89.48	-172.05	-90.03
Free Cash Flow Per Share	-3.04	-2.71	-1.65	-3.54	-2.10
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-340.16%	-390.52%	-201.41%	-476.01%	-396.26%
Profit Margin	-314.90%	-354.85%	-186.98%	-466.93%	-393.93%
FCF Margin	-313.73%	-333.91%	-116.23%	-445.42%	-302.61%
EBITDA	-266.81	-196.6	-141.41	-173.06	-111.8
EBITDA Margin	-317.71%	-360.41%	-183.68%	-448.03%	-375.81%
EBIT	-285.67	-213.03	-155.06	-183.87	-117.89
EBIT Margin	-340.16%	-390.52%	-201.41%	-476.01%	-396.26%
Effective Tax Rate	-0.29%	-0.14%	0.00%	0.00%	-0.11%

Updated Nov 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q